160 related articles for article (PubMed ID: 32871798)
1. Prognostic Role of the Platelet-to-Lymphocyte Ratio for Patients With Metastatic Colorectal Cancer Treated With Aflibercept.
Matsuda A; Yamada T; Matsumoto S; Shinji S; Ohta R; Sonoda H; Shinozuka E; Sekiguchi K; Suzuki H; Yoshida H
In Vivo; 2020; 34(5):2667-2673. PubMed ID: 32871798
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI.
Catalano M; Lavacchi D; Giommoni E; Shabani S; Guidolin A; Brugia M; Petrioli R; Ramello M; Pillozzi S; Antonuzzo L; Roviello G
Future Oncol; 2023 Dec; 19(38):2537-2546. PubMed ID: 38050741
[TBL] [Abstract][Full Text] [Related]
3. Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.
Satake H; Ando K; Oki E; Shimokawa M; Makiyama A; Saeki H; Tsuji A; Mori M
BMC Cancer; 2020 Nov; 20(1):1116. PubMed ID: 33203393
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.
Fernández Montes A; López López C; Argilés Martínez G; Páez López D; López Muñoz AM; García Paredes B; Gutiérrez Abad D; Castañón López C; Jiménez Fonseca P; Gallego Plazas J; López Doldán MC; Martínez de Castro E; Sánchez Cánovas M; Tobeña Puyal M; Llorente Ayala B; Juez Martel I; López Flores M; Carmona-Bayonas A
Oncologist; 2019 Aug; 24(8):e687-e695. PubMed ID: 31147489
[TBL] [Abstract][Full Text] [Related]
5. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer.
Chong DQ; Manalo M; Imperial M; Teo P; Yong G; Ng M; Tan IB; Choo SP; Chua C
Asia Pac J Clin Oncol; 2016 Sep; 12(3):275-83. PubMed ID: 27075236
[TBL] [Abstract][Full Text] [Related]
7. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
8. AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.
Pentheroudakis G; Kotoula V; Koliou GA; Karavasilis V; Samantas E; Aravantinos G; Kalogeropoulou L; Souglakos I; Kentepozidis N; Koumakis G; Sgouros J; Zarkavelis G; Efstratiou I; Laschos K; Petraki C; Tikas I; Poulios C; Voutsina A; Goudopoulou A; Bafaloukos D; Vrettou E; Kalogera-Fountzila A; Pectasides D; Fountzilas G
Clin Colorectal Cancer; 2018 Dec; 17(4):e631-e637. PubMed ID: 29980490
[TBL] [Abstract][Full Text] [Related]
9. Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
Vera R; Mata E; González E; Juez I; Alonso V; Iranzo P; Martínez NP; López C; Cabrera JM; Safont MJ; Ruiz-Casado A; Salgado M; González B; Escudero P; Rivera F; Pericay C
Int J Colorectal Dis; 2020 Apr; 35(4):739-746. PubMed ID: 32062727
[TBL] [Abstract][Full Text] [Related]
10. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ
Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268
[TBL] [Abstract][Full Text] [Related]
11. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.
Van Cutsem E; Joulain F; Hoff PM; Mitchell E; Ruff P; Lakomý R; Prausová J; Moiseyenko VM; van Hazel G; Cunningham D; Arnold D; Schmoll HJ; Ten Tije AJ; McKendrick J; Kröning H; Humblet Y; Grávalos C; Le-Guennec S; Andria M; Dochy E; Vishwanath RL; Macarulla T; Tabernero J
Target Oncol; 2016 Jun; 11(3):383-400. PubMed ID: 26706237
[TBL] [Abstract][Full Text] [Related]
12. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
Ruff P; Van Cutsem E; Lakomy R; Prausova J; van Hazel GA; Moiseyenko VM; Soussan-Lazard K; Dochy E; Magherini E; Macarulla T; Papamichael D
J Geriatr Oncol; 2018 Jan; 9(1):32-39. PubMed ID: 28807738
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers.
Fernández Montes A; Martínez Lago N; Covela Rúa M; de la Cámara Gómez J; González Villaroel P; Méndez Méndez JC; Jorge Fernández M; Salgado Fernández M; Reboredo López M; Quintero Aldana G; Luz Pellón Augusto M; Graña Suárez B; García Gómez J
Cancer Med; 2019 Mar; 8(3):882-889. PubMed ID: 30690930
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
Feliu J; Díez de Corcuera I; Manzano JL; Valladares-Ayerbes M; Alcaide J; García García T; Vera R; Sastre J
Clin Transl Oncol; 2017 Apr; 19(4):498-507. PubMed ID: 27718155
[TBL] [Abstract][Full Text] [Related]
15. MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer.
Matikas A; Souglakos J; Katsaounis P; Kotsakis A; Kouroupakis P; Pantazopoulos N; Kentepozidis N; Nikolaidi A; Messaritakis I; Tzovara I; Hatzidaki D; Prinarakis E; Georgoulias V
Target Oncol; 2019 Jun; 14(3):285-293. PubMed ID: 31203498
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab.
Artaç M; Uysal M; Karaağaç M; Korkmaz L; Er Z; Güler T; Börüban MC; Bozcuk H
J Gastrointest Cancer; 2017 Jun; 48(2):176-180. PubMed ID: 27714653
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.
Auvray M; Tougeron D; Auclin E; Moulin V; Artru P; Hautefeuille V; Hammel P; Lecomte T; Locher C; Sickersen G; Coriat R; Lecaille C; Vernerey D; Taieb J; Pernot S
Clin Colorectal Cancer; 2020 Mar; 19(1):39-47.e5. PubMed ID: 31648924
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
[TBL] [Abstract][Full Text] [Related]
19. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
Kashiwa M; Matsushita R
Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
[TBL] [Abstract][Full Text] [Related]
20. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
Élez E; Gómez-España MA; Grávalos C; García-Alfonso P; Ortiz-Morales MJ; Losa F; Díaz IA; Graña B; Toledano-Fonseca M; Valladares-Ayerbes M; Polo E; Salgado M; Martínez de Castro E; Safont MJ; Salud A; Ruiz-Casado A; Tabernero J; Riesco MDC; Rodriguez-Ariza A; Aranda E
Br J Cancer; 2022 Apr; 126(6):874-880. PubMed ID: 34937947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]